NASDAQ:CTRV - ContraVir Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.32 -0.01 (-3.03 %)
(As of 01/23/2019 11:05 AM ET)
Previous Close$0.3256
Today's Range$0.32 - $0.3256
52-Week Range$0.21 - $2.96
Volume11,081 shs
Average Volume82,477 shs
Market Capitalization$5.30 million
P/E RatioN/A
Dividend YieldN/A
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.

Receive CTRV News and Ratings via Email

Sign-up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CTRV



Sales & Book Value

Annual SalesN/A
Book Value$0.27 per share



Market Cap$5.30 million
OptionableNot Optionable

ContraVir Pharmaceuticals (NASDAQ:CTRV) Frequently Asked Questions

What is ContraVir Pharmaceuticals' stock symbol?

ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV."

When did ContraVir Pharmaceuticals' stock split? How did ContraVir Pharmaceuticals' stock split work?

Shares of ContraVir Pharmaceuticals reverse split before market open on Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 28th 2018. An investor that had 100 shares of ContraVir Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were ContraVir Pharmaceuticals' earnings last quarter?

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) released its earnings results on Wednesday, November, 14th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter. View ContraVir Pharmaceuticals' Earnings History.

What price target have analysts set for CTRV?

1 brokers have issued 1 year target prices for ContraVir Pharmaceuticals' stock. Their forecasts range from $32.00 to $32.00. On average, they expect ContraVir Pharmaceuticals' share price to reach $32.00 in the next twelve months. This suggests a possible upside of 9,900.0% from the stock's current price. View Analyst Price Targets for ContraVir Pharmaceuticals.

What is the consensus analysts' recommendation for ContraVir Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraVir Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraVir Pharmaceuticals.

Has ContraVir Pharmaceuticals been receiving favorable news coverage?

News stories about CTRV stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ContraVir Pharmaceuticals earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days.

Are investors shorting ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 368,129 shares, a drop of 36.1% from the December 14th total of 576,453 shares. Based on an average daily volume of 185,457 shares, the short-interest ratio is presently 2.0 days. Currently, 2.3% of the company's stock are short sold. View ContraVir Pharmaceuticals' Current Options Chain.

Who are some of ContraVir Pharmaceuticals' key competitors?

Who are ContraVir Pharmaceuticals' key executives?

ContraVir Pharmaceuticals' management team includes the folowing people:
  • Dr. John Z. Sullivan-Bolyai, Part-Time Consultant & Member of Scientific Advisory Board (Age 70)
  • Dr. Robert T. Foster BSc (Pharm), Pharm.D., Ph.D., CEO, Chief Scientific Officer & Director (Age 60)
  • Mr. John T. Cavan, Chief Financial Officer (Age 60)
  • Sharen Pyatetskaya, Director of Investor Relations

How do I buy shares of ContraVir Pharmaceuticals?

Shares of CTRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraVir Pharmaceuticals' stock price today?

One share of CTRV stock can currently be purchased for approximately $0.32.

How big of a company is ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals has a market capitalization of $5.30 million. ContraVir Pharmaceuticals employs 21 workers across the globe.

What is ContraVir Pharmaceuticals' official website?

The official website for ContraVir Pharmaceuticals is

How can I contact ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals' mailing address is 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837. The biopharmaceutical company can be reached via phone at 732-902-4000 or via email at [email protected]

MarketBeat Community Rating for ContraVir Pharmaceuticals (NASDAQ CTRV)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  261
MarketBeat's community ratings are surveys of what our community members think about ContraVir Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel